The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Intravenous Immunoglobulin Market Over The 2026–2030 Period?
The intravenous immunoglobulin market size has experienced robust growth in recent years. It is projected to expand from $15.57 billion in 2025 to $16.86 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. Historically, this growth can be attributed to factors such as the increasing prevalence of primary immunodeficiency diseases, advancements in immunoglobulin purification techniques, increased hospital-based IVIG administration, growing awareness about autoimmune disorders, and the expansion of IVIG production facilities.
The intravenous immunoglobulin market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $23.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. Key factors driving this growth include a rising preference for home-based IVIG treatment, the introduction of biosimilar IVIG products, the incorporation of automated infusion technologies, wider use in neurological conditions, and the expansion of immunoglobulin therapies into new markets. Significant developments anticipated during this period encompass individualized immunoglobulin therapy, IVIG delivery in home settings, the evolution and acceptance of biosimilars, improved purification and safety measures, and automated infusion systems.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp
Which Major Factors Are Driving The Expansion Of The Intravenous Immunoglobulin Market?
The growing geriatric population is anticipated to drive the intravenous immunoglobulin market forward. The geriatric demographic refers to individuals over 65 years of age. As people age, their immune systems often function improperly, leading to a lack of antibodies. Therefore, they need immunoglobulins to provide them with necessary antibodies. This increases the demand for intravenous immunoglobulins and propels the intravenous immunoglobulin market forward. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. This age group’s percentage of the overall population is also expected to ascend from 17% to 23% during the same period. As a result, the expanding geriatric population will fuel the growth of the intravenous immunoglobulin market forward.
How Is The Intravenous Immunoglobulin Market Segmented Across Key Categories?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
Which Upcoming Trends Are Expected To Influence The Intravenous Immunoglobulin Market?
Leading companies in the intravenous immunoglobin market are concentrating on launching innovative products, such as plasma-derived medicines, and securing their approval from federal bodies, including the US FDA, to achieve a competitive advantage. The introduction of an FDA-approved advanced IVIG solution signifies the U.S. Food and Drug Administration’s endorsement of a novel intravenous immunoglobulin (IVIG) therapy for addressing specific medical conditions. For example, in June 2024, Biotest AG, a Germany-based provider of plasma proteins and products, announced its first U.S. Food and Drug Administration (FDA) approval for Yimmugo, intended for the treatment of primary immunodeficiencies. As an intravenous immunoglobulin, Yimmugo consists of pooled human plasma-derived immunoglobulin G (IgG), which is essential for supporting the immune systems of patients with PIDs. This approval coincides with growing demand for plasma-derived therapies, emphasizing the requirement for effective treatments for individuals with compromised immune systems. Yimmugo enhances Grifols’ existing assortment of intravenous and subcutaneous immunoglobulins, thereby presenting more choices for patients who rely on these vital medicines.
Who Are The Dominant Players Shaping The Intravenous Immunoglobulin Market Landscape?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
Read the full intravenous immunoglobulin market report here:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Which Region Currently Holds The Largest Share Of The Intravenous Immunoglobulin Market?
North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Intravenous Immunoglobulin Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp
Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2026, By The Business Research Company
Intravenous Immunoglobulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Immunoglobulins Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
Subcutaneous Immunoglobulin Scig Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model